Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells

References

• Marcus KJ, Sandlund JT. Pediatric leukemias and lymphomas. In: Leonard L. Gunderson Joel E. Tepper, editor. Clinical radiation oncology. 3rd ed.. Amsterdam: Elsevier; 2012. p. 1479–1488.
   Google Scholar
• Szczepan T, Van Der Velden VHJ, Van Dongen JJM. Classification systems for acute and chronic leukaemias. Best Pract Res Clin Haematol. 2003;16:561–582.
   PubMed Web of Science ®Google Scholar
• Brown PA, Wieduwilt M, Logan A, et al. Guidelines insights: acute lymphoblastic leukemia, version 1.2019. J Natl Compr Cancer Netw. 2019;17:414–423. doi:10.6004/jnccn.2019.0024
   PubMed Web of Science ®Google Scholar
• Raetz EA, Teachey TD. T-cell acute lymphoblastic leukemia. Am Soc Hematol. 2016;2016:580–588. doi:10.1182/asheducation-2016.1.580
   PubMedGoogle Scholar
• Möricke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127:2101–2112. doi:10.1182/blood-2015-09-670729.
   PubMed Web of Science ®Google Scholar
• Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14:199–209. doi:10.1016/S1470-2045(12)70600-9
   PubMed Web of Science ®Google Scholar
• Tissing WJE, Meijerink JPP, Den Boer ML, et al. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia. 2003;17:17–25. doi:10.1038/sj.leu.2402733
   PubMed Web of Science ®Google Scholar
• Tsai SY, Carlstedt-duke J, Weigel NL, et al. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell. 1987;55:361–369. doi:10.1016/0092-8674(88)90059-1.
   Web of Science ®Google Scholar
• Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA. 1994;91:752–756. doi:10.1073/pnas.91.2.752
   PubMed Web of Science ®Google Scholar
• Harmon JM, Norman MR, Fowlkes BJ, et al. Dexamethasone induces irreversible G1 arrest and death of a human lymphoid cell line. J Cell Physiol. 1979;98:267–278. doi:10.1002/jcp.1040980203
   PubMed Web of Science ®Google Scholar
• Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980;284:555–556. doi:10.1038/284555a0.
   PubMed Web of Science ®Google Scholar
• Beesley AH, Palmer M-L, Ford J, et al. Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer. 2006;95:1537–1544. doi:10.1038/sj.bjc.6603447
   PubMed Web of Science ®Google Scholar
• Wandler AM, Huang BJ, Craig JW, et al. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2020;34:2025–2037. doi:10.1038/s41375-020-0748-6
   PubMed Web of Science ®Google Scholar
• Gao J, Liu W. Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis. Eur Rev Med Pharmacol Sci. 2018;22:7858–7866. doi:10.26355/eurrev_201811_16411.
   PubMed Web of Science ®Google Scholar
• Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524–2539. doi:10.3324/haematol.2020.247031
   PubMed Web of Science ®Google Scholar
• Tsai T-H, Chen C-F. Identification and determination of honokiol and magnolol from Magnolia officinalis by high-performance liquid chromatography with photodiode-array UV detection. J Chromatogr. 1992;598:143–146. doi:10.1016/0021-9673(92)85125-D
   Web of Science ®Google Scholar
• Ho K, Tsai C, Chen C, et al. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phyther Res. 2001;141:139–141. doi:10.1002/ptr.736
   Google Scholar
• Ou H-C, Chou F-P, Lin T-M, et al. Protective effects of honokiol against oxidized LDL-induced cytotoxicity and adhesion molecule expression in endothelial cells. Chem Biol Interact. 2006;161:1–13. doi:10.1016/j.cbi.2006.02.006.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang T, Zhu J, et al. Honokiol attenuates lipotoxicity in hepatocytes via activating SIRT3 – AMPK mediated lipophagy. Chin Med. 2021;16:1–13. doi:10.1186/s13020-021-00528-w.
   PubMed Web of Science ®Google Scholar
• Usach I, Alaimo A, Fern J, et al. Magnolol and honokiol: two natural compounds with similar chemical structure but different physicochemical and stability properties. Pharmaceutics. 2021;13:1–14. doi:10.3390/pharmaceutics13020224.
   Web of Science ®Google Scholar
• Lee Y, Mo Y, Lee C, et al. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther. 2011;130:157–176. doi:10.1016/j.pharmthera.2011.01.010
   PubMed Web of Science ®Google Scholar
• Li HY., Ye HG, Chen CQ, et al. Honokiol induces cell cycle arrest and apoptosis via inhibiting claa I histone deacetylases in acute myeloid leukemia. J Cell Biochem. 2015;116:287–298. doi:10.1002/jcb.24967.
   PubMed Web of Science ®Google Scholar
• Pan J, Lee Y, Zhang Q, et al. Honokiol decreases lung cancer metastasis through inhibition of the STAT3 signaling pathway. Cancer Prev Res. 2018;10:133–141. doi:10.1158/1940-6207.CAPR-16-0129.
   Web of Science ®Google Scholar
• Prasad R, Singh T, Katiyar KS. Honokiol inhibits ultraviolet immunosuppression through inhibition of ultraviolet-induced inflammation and DNA hypermethylation in mouse skin. Sci Rep. 2017;7（1）:1–14. doi:10.1038/s41598-017-01774-5.
   Web of Science ®Google Scholar
• Lahans T. Integrating conventional and Chinese medicine in cancer care. 229–251, 2007.
   Google Scholar
• Wang X, Beitler JJ, Wang H, et al. Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. PLoS One. 2014;9(2):e86369. doi:10.1371/journal.pone.0086369
   PubMed Web of Science ®Google Scholar
• Ishitsuka K, Hideshima T, Hamasaki M, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood. 2005;106:1794–1800. doi:10.1182/blood-2005-01-0346
   PubMed Web of Science ®Google Scholar
• Eliaz I, Weil E. Intravenous honokiol in drug-resistant cancer: two case reports. Integr Cancer Ther. 2020;19:1–5. doi:10.1177/1534735420922615.
   Web of Science ®Google Scholar
• Ong CP, Lee WL, Tang YQ, et al. Honokiol: a review of its anticancer potential and mechanisms. Cancers (Basel). 2020;12:1–44. doi:10.3390/cancers12010048.
   Web of Science ®Google Scholar
• Kim DW, Ko SM, Jeon YJ, et al. Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1. Int J Oncol. 2013;43:1103–1110. doi:10.3892/ijo.2013.2028
   PubMed Web of Science ®Google Scholar
• Dai X, Li RZ, Jiang ZB, et al. Honokiol inhibits proliferation, invasion and induces apoptosis through targeting Lyn kinase in human lung adenocarcinoma cells. Front Pharmacol. 2018;9:1–8. doi:10.3389/fphar.2018.00558.
   PubMed Web of Science ®Google Scholar
• Vermeulen K, Berneman ZN, Van Bockstaele RD. Cell cycle and apoptosis. Cell Prolif. 2003;36:165–175. doi:10.1046/j.1365-2184.2003.00267.x
   PubMed Web of Science ®Google Scholar
• Wiman KG, Zhivotovsky B. Understanding cell cycle and cell death regulation provides novel weapons against human diseases. J Intern Med. 2017;281:483–495. doi:10.1111/joim.12609
   PubMed Web of Science ®Google Scholar
• Muniraj N, Siddharth S, Shriver M, et al. Induction of STK11-dependent cytoprotective autophagy in breast cancer cells upon honokiol treatment. Cell Death Discov. 2020;6:1–15. doi:10.1038/s41420-020-00315-w.
   Web of Science ®Google Scholar
• Medh RD, Saeed MF, Johnson BH, et al. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase a pathways: correlation with c-Myc suppression. Cancer Res. 1998;58:3684–3693.
   PubMed Web of Science ®Google Scholar
• Thompson EB, Thulasi R, Saeed MF, et al. Glucocorticoid antagonist RU 486 reverses agonist-induced apoptosis and C-Myc repression in human leukemic CEM-C7 cells. Ann Ny Acad Sci. 1995;761:261–275. doi:10.1111/j.1749-6632.1995.tb31383.x
   PubMed Web of Science ®Google Scholar
• Zhou F, Medh RD, Thompson EB. Glucocorticoid mediated transcriptional repression of c-myc in apoptotic human leukemic CEM cells. J Steroid Biochem Mol Biol. 2000;73:195–202. doi:10.1016/S0960-0760(00)00080-7
   PubMed Web of Science ®Google Scholar
• Medh RD, Wang A, Zhou F, et al. Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells. Oncogene. 2001;20:4629–4639. doi:10.1038/sj.onc.1204680
   PubMed Web of Science ®Google Scholar
• Kośmider K, Karska K, Kozakiewicz A, et al. Overcoming steroid resistance in pediatric acute lymphoblastic leukemia—the state-of-the-art knowledge and future prospects. Int J Mol Sci. 2022;23(7):3795. doi:10.3390/ijms23073795
   PubMed Web of Science ®Google Scholar
• Rauf A, Patel S, Imran M, et al. Honokiol: an anticancer lignan. Biomed Pharmacother. 2018;107:555–562. doi:10.1016/j.biopha.2018.08.054
   PubMed Web of Science ®Google Scholar